Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study

Acta diabetologica latina
S B SolerteE Ferrari

Abstract

An association between renal microvascular complications and hemorheological alterations has been suggested in diabetes mellitus. Therefore, a hemorheologic approach in the treatment of diabetic microproteinuria has been proposed. Eighty-two type I and type II diabetic patients with microproteinuria were randomized and assigned to two different protocols: protocol A, patients treated with pentoxifylline (Trental 400); protocol B, patients without hemorheologic treatment, in whom hypoglycemic therapy was just more strictly enforced. A significant improvement of the hemorheologic pattern and a significant marked reduction of albumin excretion rate and proteinuria was found in diabetic patients treated with pentoxifylline, independently of the degree of metabolic control. These results were readily achieved and were confirmed throughout the study. Moreover, these results were comparable to those obtained in diabetic patients of protocol B. Pentoxifylline might therefore be considered as the first useful therapeutic agent in the treatment of diabetic microproteinuria.

References

Sep 1, 1976·Journal of Clinical Pathology·H L ReidT L Dormandy
Jun 1, 1985·The Journal of Clinical Endocrinology and Metabolism·E EsmatjesD Figuerola
Sep 1, 1965·Immunochemistry·G ManciniJ F Heremans
Feb 9, 1984·The New England Journal of Medicine·C E Mogensen
Jul 12, 1984·The New England Journal of Medicine·C E Mogensen, C K Christensen
Jan 1, 1980·La Ricerca in Clinica E in Laboratorio·J T Whicher, E S Parry

❮ Previous
Next ❯

Citations

Apr 9, 2005·Journal of the Chinese Medical Association : JCMA·Shuei-Liong LinBor-Shen Hsieh
Mar 3, 2009·Cytokine & Growth Factor Reviews·Juan F Navarro-GonzálezJavier García
Feb 14, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert M PerkinsChristina M Yuan
Sep 15, 2004·Nephrology·Shuei-Liong LinWan-Yu Chen
Jun 18, 2015·Clinical Pharmacology and Therapeutics·P-C WuUNKNOWN Kidney Consortium
Jun 13, 2015·Journal of Diabetes Research·Stephanie Toth-Manikowski, Mohamed G Atta
May 1, 1995·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
Mar 19, 2015·Journal of Diabetes Research·Javier Donate-CorreaJuan F Navarro-González
May 4, 2011·Nature Reviews. Nephrology·Juan F Navarro-GonzálezJavier García-Pérez
Apr 7, 1990·BMJ : British Medical Journal·S BjörckM Aurell
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Dan ShanGuan J Liu
May 16, 2019·Terapevticheskiĭ arkhiv·I T MurkamilovA A Bayzhigitova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.